Elanix Biotechnologies : The Management and Supervisory Board will propose to the annual general meeting a capital increase against cash contributions up to 50% granting indirect subscription rights - 13.07.2017

Berlin, 13 July 2017 - the Management and Supervisory Board of Elanix Biotechnologies AG will, amongst others, propose to the annual general meeting 2017 a share capital increase from EUR 6,799,200.00 by EUR 3,399,600.00 up to EUR 10,198,800.00 granting subscription rights to the existing shareholders. The issue price shall be determined at a later stage. The capital increase shall be used for the further funding of the growth and to strengthen the share capital.

The invitation to the general meeting with the proposed resolutions of the Management, which shall be held on August 24, 2017 in Berlin, will be announced in the Bundesanzeiger and made available on the website of the company within the next couple days.

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland, with offices in Potsdam, and is listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.

This publication contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Elanix Biotechnologies AG disclaims any obligation to update these forward-looking statements.

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in

the United States of America (the "United States"), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities

Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

This announcement also does not constitute a prospectus within the meaning of the EU Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 as amended ("Prospectus Directive").